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Terlipressine is a long-acting synthetic analogue of vasopressine used in the treatment of complications 
of liver cirrhosis such as hepatorenal syndrome (HRS) or variceal bleeding. Some of the most common 
adverse effects are abdominal cramps, headaches, bradycardia, and peripheral vasoconstriction. Despite 
being rare, malignant arrhythmia and skin necrosis can lead to fatal outcome. We report a female patient 
with HRS type 1 who received terlipressine intravenously for 7 days. Since there was no evidence of 
clinical improvement, on the 6th day norepinephrine was introduced as a second vasopressor. The day 
after the second drug was added, bullous skin changes occurred on her extremities and trunk. Those 
changes quickly progressed to necrosis and repetitive polymorphic VT with prolonged QTc intervals 
were also noted. Because of the severe adverse effects terlipressine was discontinued which led to an 
improvement of the skin lesions and cessation of malignant arrhythmia. Despite treatment, HRS led to 
multiple organ failure subsequently causing death of the patient. Although it is very effective in the 
treatment of HRS, terlipressine carries certain risk of side effects. Potentially lethal adverse effects are 
rare but nevertheless, it is important to know them in order to be able to recognise them as soon as 
possible. 
  
